



Versameb Chief Executive Officer to Present at LSX Investival Showcase Conference

10 November 2022, Basel, Switzerland: Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s proprietary mRNA engineering technology platform, *VERSagile*, at the [LSX Investival Showcase Conference](#) taking place on 14 November 2022 at Old Billingsgate in London, UK.

The Investival Showcase Conference is focused on connecting life science and healthcare companies with investors and partners to provide a networking opportunity for early, growth-stage and public Biotech, Medtech, Digital Health and Women’s Health companies. The Conference offers headliner and stage speakers plus the opportunity to deliver Company news and deal flow through various sessions profiling each Company with an active and curated audience of investors and strategics.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment of Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

Details of Versameb’s presentation are as follows:

[LSX Investival Showcase Conference](#)

Date: 14 November 2022, Old Billingsgate, London, UK

Presentation by: Klaas Zuideveld

Session: “Biotech Growth Stage - Pre-Series B”

Time: 11.30-11.45 GMT

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to have the opportunity to discuss the positive progress that Versameb has achieved over the past year as we advance our proprietary platform *VERSagile* to provide treatments to patients suffering with Stress Urinary Incontinence (SUI) and solid tumors. We look forward to an exciting 2023 of key important Company milestones as we further advance our pioneering next generation RNA therapeutics.”

If you would like to meet with the Versameb team at the above event, please contact us using the details provided below. For more information, please visit us at <https://versameb.com/upcoming-conferences-events/>

-Ends-

Contact for media enquiries:

Versameb

Dr Klaas Zuideveld, CEO

lr@versameb.com



Optimum Strategic Communications

Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt

Tel: +44 (0)20 3882 9621

versameb@optimumcomms.com

About Versameb

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, *VERSagile*, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on [LinkedIn](#).

About LSX Investival Showcase Conference

LSX is the Life Science eXecutive partnering community that connects biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. For further information, please visit www.lsxleaders.com/investival-showcase